Research programme: cardiovascular disorder therapies - Cryptome PharmaceuticalsAlternative Names: Cardiovascular disorder therapies research programme - Cryptome Pharmaceuticals; CR 001
Latest Information Update: 16 Jul 2016
At a glance
- Originator Cryptome Pharmaceuticals
- Class Proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in Australia
- 22 Feb 2005 Preclinical trials in Thrombosis in Australia (unspecified route)